STS Disease Overview and General Principles
The Importance of a Multidisciplinary Team in STS Diagnosis and Treatment Planning
Advanced STS Treatment
- Therapeutic Approach Overview
- Selecting Among Treatment Options in the First-line and Second-line Settings
- Evolving Topics and Ongoing Clinical Trials
Insights to Help Community Oncologists in Their Everyday Practice
- Overall Referral Considerations
- Best Practices in Community Oncology and Expert Center Collaboration, Referral, and Patient Transfers
Question and Answer Session
Date / Time
Shreyas Patel, MD
Robert R. Herring Distinguished Professor of Medicine
Medical Director, Sarcoma Center
University of Texas MD Anderson Cancer Center
William Tap, MD
Chief, Sarcoma Medical Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Vicki Keedy, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Richard Riedel, MD
Associate Director for Clinical and Translational Research
Duke Sarcoma Program
Duke Cancer Institute
Associate Professor with Tenure
Division of Medical Oncology
Duke University Medical Center
Durham, North Carolina
Brian Van Tine, MD
Associate Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with soft tissue sarcoma (subtypes with nonspecific histologies) and establish more efficient infrastructures to support physician collaboration and timely, more prevalent referrals among community oncologists and expert sarcoma treatment centers.
This program is intended for oncologists and other oncology healthcare providers who care for patients with STS.
- Discuss contemporary multidisciplinary strategies used in the management of advanced STS to formulate treatment plans for patients
- Plan individualized treatment strategies based on disease characteristics as well as patient age/fitness, comorbidities, and preferences
- Evaluate key safety and efficacy data on recently approved therapies for advanced STS in the context of evolving treatment paradigms and multimodality sequencing in multiple lines of care
- Apply the available data, treatment guidelines, and expert recommendations to select therapy for advanced STS
- Facilitate physician collaboration and referrals among community oncologists and sarcoma treatment centers
- Identify patients who are eligible to enroll on ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-518-L01-P.
Type of Activity
Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.